This Viewpoint discusses vaccine costs and policy and explains the importance of balancing these factors to provide optimal care while restricting spending on costly interventions with limited benefit.
This Viewpoint argues that if value-based insurance designs are to reduce expenditures, they must offer disincentives to purchasing low-value care in addition to providing incentives for purchasing high-value care.
This Special Communication summarizes published evidence about the causes of elevated prescription drug prices in the United States and proposes policy options to mitigate the effects of high prices while preserving incentives for development and innovation.
This Viewpoint discusses controversies surrounding the US Food and Drug Administration’s 2016 approval of eteplirsen for treatment of Duchenne muscular dystrophy.
This Medical News article discusses recent efforts by the Department of Veterans Affairs to extend new hepatitis C treatments to all veterans within its health care system.
This pharmacoepidemiology study uses NHANES data to describe trends in prescription drug use among US adults between 1999 and 2012.
This Viewpoint describes 6 pilot programs from the Centers for Medicare & Medicaid Services aimed at lowering Part B drug costs by discussing their application to cancer treatments.
This network meta-analysis of randomized clinical trials compares the relative efficacy and safety of glucose-lowering drugs and insulin for reducing cardiovascular mortality in patients with type 2 diabetes.
This statement from the International Antiviral Society–USA updates recommendations for the use of antiretroviral drugs (ARVs) to treat adults with established HIV infection and to prevent HIV infection among persons at risk of infection.